

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	15.10.2025	7725100-00020	Date of first issue: 06.01.2021

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Substance/Mixture : Pharmaceutical

Recommended restrictions on use : Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD
Innishannon
County Cork - Ireland

Telephone : 353 214329300

E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 1B
Specific target organ toxicity - repeated exposure, Category 1

H360D: May damage the unborn child.
H372: Causes damage to organs through prolonged or repeated exposure.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Signal word : Danger

Hazard statements : H360D May damage the unborn child.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Pembrolizumab / Berahyaluronidase alfa Sub-cutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	15.10.2025	7725100-00020	Date of first issue: 06.01.2021

H372 Causes damage to organs through prolonged or repeated exposure.

Precautionary statements : **Prevention:**

P201 Obtain special instructions before use.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Hazardous components which must be listed on the label:

Pembrolizumab

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Pembrolizumab	1374853-91-4	Repr. 1B; H360D STOT RE 1; H372 (Immune system)	>= 10 - < 20
Berahyaluronidase alfa	2636716-20-4	Resp. Sens. 1; H334	< 0.1

For explanation of abbreviations see section 16.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Pembrolizumab / Berahyaluronidase alfa Sub-cutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	15.10.2025	7725100-00020	Date of first issue: 06.01.2021

SECTION 4: First aid measures

4.1 Description of first aid measures

- | | | |
|----------------------------|---|---|
| General advice | : | In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice. |
| Protection of first-aiders | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| If inhaled | : | If inhaled, remove to fresh air.
Get medical attention. |
| In case of skin contact | : | In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse. |
| In case of eye contact | : | Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists. |
| If swallowed | : | If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water. |

4.2 Most important symptoms and effects, both acute and delayed

- | | | |
|-------|---|---|
| Risks | : | May damage the unborn child.
Causes damage to organs through prolonged or repeated exposure. |
|-------|---|---|

4.3 Indication of any immediate medical attention and special treatment needed

- | | | |
|-----------|---|---|
| Treatment | : | Treat symptomatically and supportively. |
|-----------|---|---|

SECTION 5: Firefighting measures

5.1 Extinguishing media

- | | | |
|------------------------------|---|--|
| Suitable extinguishing media | : | Water spray
Alcohol-resistant foam
Carbon dioxide (CO ₂)
Dry chemical |
| Unsuitable extinguishing | : | None known. |

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Pembrolizumab / Berahyaluronidase alfa Sub-cutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	15.10.2025	7725100-00020	Date of first issue: 06.01.2021

media

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Pembrolizumab / Berahyaluronidase alfa Sub-cutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	15.10.2025	7725100-00020	Date of first issue: 06.01.2021

certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

- | | | |
|-------------------------|---|--|
| Technical measures | : | See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section. |
| Local/Total ventilation | : | If sufficient ventilation is unavailable, use with local exhaust ventilation. |
| Advice on safe handling | : | Do not get on skin or clothing.
Do not breathe mist or vapours.
Do not swallow.
Avoid contact with eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |

7.2 Conditions for safe storage, including any incompatibilities

- | | | |
|---|---|--|
| Requirements for storage areas and containers | : | Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations. |
| Advice on common storage | : | Do not store with the following product types:
Strong oxidizing agents
Self-reactive substances and mixtures
Organic peroxides
Explosives
Gases |

7.3 Specific end use(s)

- | | | |
|-----------------|---|-------------------|
| Specific use(s) | : | No data available |
|-----------------|---|-------------------|

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Pembrolizumab / Berahyaluronidase alfa Sub-cutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	15.10.2025	7725100-00020	Date of first issue: 06.01.2021

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Pembrolizumab	1374853-91-4	TWA	450 µg/m3 (OEB 2)	Internal
Sucrose	57-50-1	OELV - 8 hrs (TWA)	10 mg/m3	IE OEL
		OELV - 15 min (STEL)	20 mg/m3	IE OEL
Berahyaluronidase alfa	2636716-20-4	TLV-C	0.06 ug/m3 (OEB 5)	Internal
	Further information: RSEN			
		Wipe limit	0.07 ug/100 cm2	

8.2 Exposure controls

Engineering measures

The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.

Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

No open handling permitted.

Totally enclosed processes and materials transport systems are required.

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Pembrolizumab / Berahyaluronidase alfa Sub-cutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	15.10.2025	7725100-00020	Date of first issue: 06.01.2021

Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 143
Filter type	:	Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state	:	liquid
Form	:	liquid
Colour	:	No data available
Odour	:	No data available
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Flash point	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
pH	:	5.5 No data available

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Pembrolizumab / Berahyaluronidase alfa Sub-cutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	15.10.2025	7725100-00020	Date of first issue: 06.01.2021

Viscosity
Viscosity, kinematic : No data available

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Vapour pressure : No data available

Relative density : No data available

Density : No data available

Relative vapour density : No data available

Particle characteristics
Particle size : Not applicable

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

Molecular weight : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Pembrolizumab / Berahyaluronidase alfa Sub-cutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	15.10.2025	7725100-00020	Date of first issue: 06.01.2021

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:

Berahyaluronidase alfa:

Acute oral toxicity : Remarks: Not classified due to lack of data.

Acute inhalation toxicity : Remarks: Not classified due to lack of data.

Acute dermal toxicity : Remarks: Not classified due to lack of data.

Skin corrosion/irritation

Not classified based on available information.

Components:

Berahyaluronidase alfa:

Remarks : Not classified due to lack of data.

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Berahyaluronidase alfa:

Remarks : Not classified due to lack of data.

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Berahyaluronidase alfa:

Result : Sensitiser

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Pembrolizumab / Berahyaluronidase alfa Sub-cutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	15.10.2025	7725100-00020	Date of first issue: 06.01.2021

Germ cell mutagenicity

Not classified based on available information.

Components:

Berahyaluronidase alfa:

Genotoxicity in vitro : Remarks: Not classified due to lack of data.

Genotoxicity in vivo : Remarks: Not classified due to lack of data.

Germ cell mutagenicity- Assessment : May cause genetic defects.

Carcinogenicity

Not classified based on available information.

Components:

Berahyaluronidase alfa:

Remarks : Not classified due to lack of data.

Reproductive toxicity

May damage the unborn child.

Components:

Pembrolizumab:

Reproductive toxicity - Assessment : May damage the unborn child., Based on data from similar materials

Berahyaluronidase alfa:

Effects on fertility : Remarks: Not classified due to lack of data.
May cause adverse reproductive effects.

Effects on foetal development : Remarks: Not classified due to lack of data.
May cause birth defects.

Reproductive toxicity - Assessment : May damage fertility. May damage the unborn child.

STOT - single exposure

Not classified based on available information.

Components:

Berahyaluronidase alfa:

Assessment : May cause damage to organs.

Remarks : Not classified due to lack of data.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Pembrolizumab / Berahyaluronidase alfa Sub-cutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	15.10.2025	7725100-00020	Date of first issue: 06.01.2021

STOT - repeated exposure

Causes damage to organs through prolonged or repeated exposure.

Components:

Pembrolizumab:

Target Organs	: Immune system
Assessment	: Causes damage to organs through prolonged or repeated exposure.

Berahyaluronidase alfa:

Assessment	: May cause damage to organs through prolonged or repeated exposure.
Remarks	: Not classified due to lack of data.

Repeated dose toxicity

Components:

Pembrolizumab:

Species	: Monkey
NOAEL	: 200 mg/kg
Application Route	: Intravenous
Exposure time	: 180 d
Remarks	: No significant adverse effects were reported

Species	: Dog
NOAEL	: 200 mg/kg
Application Route	: Intravenous
Exposure time	: 180 d
Remarks	: No significant adverse effects were reported

Berahyaluronidase alfa:

Remarks	: Not classified due to lack of data. May cause damage to organs.
---------	--

Aspiration toxicity

Not classified based on available information.

Components:

Berahyaluronidase alfa:

Not applicable

11.2 Information on other hazards

Endocrine disrupting properties

Not classified based on available information.

Product:

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Pembrolizumab / Berahyaluronidase alfa Sub-cutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	15.10.2025	7725100-00020	Date of first issue: 06.01.2021

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

Pembrolizumab:

Inhalation : Target Organs: Immune system
Symptoms: Cough, Fatigue, Nausea, pruritis, Rash, constipation, joint pain, Diarrhoea, Pneumonia, decrease in appetite, Fever, anemia, neutropenia, musculoskeletal pain, Vomiting, confusion, Headache, Shortness of breath, Hypofunction of thyroid gland, May cause respiratory arrest., May cause, immune-mediated pneumonitis, colitis, hepatitis, nephritis
Remarks: Damage to fetus possible

Berahyaluronidase alfa:

General Information : Avoid repeated exposure.
May cause eye, skin, and respiratory tract irritation.
May be harmful if swallowed.
May be harmful if inhaled.
May produce an allergic reaction.
May cause heritable genetic damage.
May cause adverse reproductive effects.
May cause birth defects.
May cause damage to organs.

Further information

Components:

Berahyaluronidase alfa:

Remarks : The toxicological properties of this material have not been fully investigated

SECTION 12: Ecological information

12.1 Toxicity

Components:

Berahyaluronidase alfa:

Toxicity to fish : Remarks: No data available
Toxicity to daphnia and other aquatic invertebrates : Remarks: No data available
Toxicity to algae/aquatic : Remarks: No data available

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Pembrolizumab / Berahyaluronidase alfa Sub-cutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	15.10.2025	7725100-00020	Date of first issue: 06.01.2021

plants

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : Remarks: No data available

Ecotoxicology Assessment

Acute aquatic toxicity : No data available

Chronic aquatic toxicity : No data available

12.2 Persistence and degradability

Components:

Berahyaluronidase alfa:

Biodegradability : Remarks: No data available

Stability in water : Remarks: No data available

12.3 Bioaccumulative potential

No data available

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Pembrolizumab / Berahyaluronidase alfa Sub-cutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	15.10.2025	7725100-00020	Date of first issue: 06.01.2021

Product	:	Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA	:	Not regulated as a dangerous good

14.2 UN proper shipping name

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA	:	Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA	:	Not regulated as a dangerous good

14.4 Packing group

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA (Cargo)	:	Not regulated as a dangerous good

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Pembrolizumab / Berahyaluronidase alfa Sub-cutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	15.10.2025	7725100-00020	Date of first issue: 06.01.2021

IATA (Passenger) : Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) : Conditions of restriction for the following entries should be considered:
Number on list 3

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59) : Not applicable

Regulation (EU) No 2024/590 on substances that deplete the ozone layer : Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable

Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable

REACH - List of substances subject to authorisation (Annex XIV) : Not applicable

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.
Not applicable

Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Pembrolizumab / Berahyaluronidase alfa Sub-cutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	15.10.2025	7725100-00020	Date of first issue: 06.01.2021

The components of this product are reported in the following inventories:

CA. DSL	:	not determined
AICS	:	not determined
IECSC	:	not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
-------------------	---	--

Full text of H-Statements

H334	:	May cause allergy or asthma symptoms or breathing difficulties if inhaled.
H360D	:	May damage the unborn child.
H372	:	Causes damage to organs through prolonged or repeated exposure if swallowed.

Full text of other abbreviations

Repr.	:	Reproductive toxicity
Resp. Sens.	:	Respiratory sensitisation
STOT RE	:	Specific target organ toxicity - repeated exposure
IE OEL	:	Ireland. List of Chemical Agents and Carcinogens with Occupational Exposure Limit Values - Code of Practice, Schedule 1 and 2
IE OEL / OELV - 8 hrs (TWA)	:	Occupational exposure limit value (8-hour reference period)
IE OEL / OELV - 15 min (STEL)	:	Occupational exposure limit value (15-minute reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonised System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organisation; ISHL

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	15.10.2025	7725100-00020	Date of first issue: 06.01.2021

- Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardisation; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organisation for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

Repr. 1B	H360D
STOT RE 1	H372

Classification procedure:

Calculation method
Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN